Did You Know?

Editor’s Picks

Latest News

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...

Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas

Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effectiveTwo mRNA biomarkers found to be particularly...

Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt

AD Ports Logistics, subsidiary of AD Ports Group’s Logistics Cluster, chosen as the Exclusive Distributor for United Arab Emirates, Qatar,...

Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy

Proprietary bi-functional ADCs target and inhibit unique Delta receptor on tumor-associated Myeloid Derived Suppressor Cells (MDSCs); increasing tumor’s susceptibility to...

error: Content is protected !!